We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Campaign to Increase Compliance with Take-Home Colorectal Screening Test

By HospiMedica staff writers
Posted on 11 Apr 2008
A novel campaign has been launched help increase compliance with take-home colorectal screening tests. More...
The campaign aims to break down barriers to compliance with fecal occult blood tests and increase screening with convenient take-home screening tools. The goal of the new campaign is to have five million people complete their annual testing over the next five years.

In the United States, nearly 60 % of women have an annual Pap test (for cervical cancer) and as many as 79 % of men receive prostate-specific antigen (PSA) screening every year for prostate cancer. In one randomized clinical study, only 31 % of patients (n = 1818) completed an at-home colorectal screening test. Despite the availability of these convenient and effective diagnostic tests, nearly 150,000 men and women in the United States will be diagnosed with colorectal cancer this year, and one-third of these patients will ultimately succumb to the disease. When found early and treated, the five-year relative survival rate for colon cancer is 90%, but less than 40% of colorectal cancers are found early.

Fecal occult blood tests (FOBTs), including the newer fecal immunochemical tests (FITs), detect blood in the stool that might indicate colorectal cancer or other lower gastrointestinal diseases. These screening tests help identify individuals that are candidates for colonoscopy, even if they do not have overt symptoms of colorectal cancer. This may mean the disease is in its early, more treatable stages, or that they may have precancerous polyps that can be removed during colonoscopy.

Quest Diagnostics (Madison, NJ, USA) is launching the campaign at the end of Cancer Awareness Month "because we want people to remember that this disease strikes every day of every month,” said Stephen C. Suffin, M.D., the company's clinical pathologist and interim chief laboratory officer. "Our Challenge is designed to encourage people 50 and over and those at risk to complete annual screening with American Cancer Society [ACS] recommended tests, such as the FDA-[U.S. Food and Drug Administration]-approved, InSure FIT test and its painless, noninvasive Blue-Brush Method.”

The Challenge urges individuals to talk to their healthcare providers about annual colorectal cancer screening using the InSure FIT take-home test, developed by Quest, and in turn, to challenge friends and family members to "have the guts” to get screened, too. Challenge participants can also send an attention-grabbing "Happy, Healthy Colon” e-card to friends and relatives as a reminder to be screened annually. Medical professionals can access the latest scientific data on InSure FIT, up-to-date colorectal cancer screening guidelines and resources, and patient education materials that can help guide discussions with their patients about colorectal cancer screening.

Quest Diagnostics is a provider of diagnostic testing, information, and services that patients and doctors need to make better healthcare decisions. The company offers access to diagnostic testing services through its national network of laboratories and patient service centers, and provides interpretive consultation through its medical and scientific staff.


Related Links:
Quest Diagnostics

Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
New
Automated Coagulation Analyzer
Hemolumi H6
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A new study identifies distinct metabolomic signatures in maternal blood associated with both the timing and type of early birth (Image credit: iStock)

Maternal Blood Biomarkers Identify Risk of Preterm and Early-Term Birth

Preterm and early-term births can lead to lasting complications because vital organs continue to mature during the final weeks of pregnancy. Babies born too soon face increased risks of breathing difficulties,... Read more

Microbiology

view channel
Image: Graphical Abstract (Emery, J. K., V. Nemidkanam, N. Colon, et al. Journal of Extracellular Vesicles (2026). https://doi.org/10.1002/jev2.70286)

Extracellular Vesicle Biomarker May Enable Noninvasive Monitoring of H. pylori

Helicobacter pylori infects an estimated 43.9% of the global population, affecting approximately 4.4 billion people worldwide. In many regions, including Africa, Eastern Europe, and Southeast Asia, prevalence... Read more

Industry

view channel
Image

QIAGEN Enhances QIAcuity Platform with Gene Expression and Multiplexing Tools

QIAGEN (Venlo, Netherlands) has introduced additions to its QIAcuity dPCR ecosystem that focus on gene expression, expanded assay content, and workflow standardization for life sciences and biopharma users.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.